A luminal unfolding microneedle injector for oral delivery of macromolecules

• Main Authors: Abramson, Alex (Author), Caffarel Salvador, Ester (Author), Soares, Vance (Author), Minahan Jr, Daniel J (Author), Tian, Ryan Yu (Author), Lu, Xiaoya (Author), Dellal, David (David M.) (Author), Gao, Yuan (Author), Kim, Soyoung (Author), Wainer, Jacob P (Author), Collins, Joy E (Author), Tamang, Siddartha M (Author), Hayward, Alison M (Author), Yoshitake, Tadayuki (Author), Lee, Hsiang-Chieh (Author), Fujimoto, James G (Author), Fels, Johannes (Author), Frederiksen, Morten Revsgaard (Author), Rahbek, Ulrik (Author), Roxhed, Niclas (Author), Langer, Robert S (Author), Traverso, Carlo Giovanni (Author)
• Other Authors: Massachusetts Institute of Technology. Department of Chemistry (Contributor), Massachusetts Institute of Technology. Institute for Medical Engineering & Science (Contributor), Massachusetts Institute of Technology. Department of Mechanical Engineering (Contributor), Massachusetts Institute of Technology. Division of Comparative Medicine (Contributor), Massachusetts Institute of Technology. Media Laboratory (Contributor), Massachusetts Institute of Technology. Research Laboratory of Electronics (Contributor), Massachusetts Institute of Technology. Department of Electrical Engineering and Computer Science (Contributor), Massachusetts Institute of Technology. Department of Biological Engineering (Contributor), Koch Institute for Integrative Cancer Research at MIT (Contributor)
• Format: Article
• Language: English
• Published: Springer Science and Business Media LLC, 2021-01-04T19:42:56Z.
• Subjects: Article
• Online Access: Get fulltext

Insulin and other injectable biologic drugs have transformed the treatment of patients suffering from diabetes1,2, yet patients and healthcare providers often prefer to use and prescribe less effective orally dosed medications3-5. Compared with subcutaneously administered drugs, oral formulations create less patient discomfort4, show greater chemical stability at high temperatures6, and do not generate biohazardous needle waste7. An oral dosage form for biologic medications is ideal; however, macromolecule drugs are not readily absorbed into the bloodstream through the gastrointestinal tract8. We developed an ingestible capsule, termed the luminal unfolding microneedle injector, which allows for the oral delivery of biologic drugs by rapidly propelling dissolvable drug-loaded microneedles into intestinal tissue using a set of unfolding arms. During ex vivo human and in vivo swine studies, the device consistently delivered the microneedles to the tissue without causing complete thickness perforations. Using insulin as a model drug, we showed that, when actuated, the luminal unfolding microneedle injector provided a faster pharmacokinetic uptake profile and a systemic uptake >10% of that of a subcutaneous injection over a 4-h sampling period. With the ability to load a multitude of microneedle formulations, the device can serve as a platform to orally deliver therapeutic doses of macromolecule drugs.
NIH (Grant EB-00244)